SCHEMBL16756358

SCHEMBL16756358

Cc1nc2ccc(O)cc2n1Cc1cc(Cl)ccc1Cl

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GALR3 O60755 2/20 0.46
NR2F2 P24468 2/20 0.46
RAB9A P51151 2/20 0.46
PPARG P37231 1/20 0.46
KMT2A Q03164 1/20 0.45
PDE2A O00408 1/20 0.45
PDE10A Q9Y233 1/20 0.45
DCTPP1 Q9H773 3/20 0.43
NPC1 O15118 1/20 0.41
TNF P01375 1/20 0.40
RPS6KA5 O75582 1/20 0.39
BRD4 O60885 1/20 0.38
LMNA P02545 1/20 0.38
PTGDR2 Q9Y5Y4 1/20 0.38
HDAC3 O15379 1/20 0.38
HDAC4 P56524 1/20 0.38
HDAC1 Q13547 1/20 0.38
HDAC7 Q8WUI4 1/20 0.38
HDAC2 Q92769 1/20 0.38
HDAC10 Q969S8 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16756460 0.90 KMT2A (0.54) GALR3NR2F2RAB9APPARGKMT2A
SCHEMBL15559800 0.85 GALR3 (0.48) GALR3NR2F2RAB9APPARGKMT2A
SCHEMBL15560376 0.83 PPARG (0.54) GALR3NR2F2RAB9APPARGKMT2A
SCHEMBL15551520 0.83 GALR3 (0.68) GALR3NR2F2RAB9AKMT2ANPC1
SCHEMBL15552553 0.82 DCTPP1 (0.57) GALR3NR2F2RAB9APPARGPDE2A
SCHEMBL15553244 0.81 CYP11B2 (0.46) GALR3NR2F2RAB9APPARGKMT2A
SCHEMBL15552143 0.80 PPARG (0.52) GALR3NR2F2RAB9APPARGKMT2A
SCHEMBL18148904 0.80 GALR3 (0.46) GALR3NR2F2RAB9APPARGKMT2A
SCHEMBL18918991 0.80 GALR3 (0.43) GALR3NR2F2RAB9APPARGKMT2A
SCHEMBL15559625 0.79 GALR3 (0.48) GALR3NR2F2RAB9APPARGKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2858983-B1 TNF-ALPHA MODULATING BENZIMIDAZOLES UCB BIOPHARMA SPRL (BE) 2018-04-18 EP disclosed
US-9550737-B2 TNF -α modulating benzimidazoles UCB BIOPHARMA SPRL (BE) 2017-01-24 US disclosed
US-20150152065-A1 TNF -Alpha Modulating Benzimidazoles UCB BIOPHARMA SPRL (BE) 2015-06-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150152065-A1 TNF -Alpha Modulating Benzimidazoles TNF, TNFRSF1A, NFKBIA GALR3 4147/4885NR2F2 4378/4885RAB9A 1951/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.